10579-67-6

Usage

Uses

Given the provided materials, the specific uses of 2-(3-chloropropanoyl)-1,2,3,4-tetrahydroisoquinoline are not explicitly stated. However, based on its structure and the general applications of tetrahydroisoquinoline derivatives, potential uses in the following areas can be hypothesized:
Used in Pharmaceutical Industry:
2-(3-chloropropanoyl)-1,2,3,4-tetrahydroisoquinoline could be used as a pharmaceutical intermediate for the synthesis of drugs targeting various medical conditions. Its unique structure may offer specific binding affinities or pharmacological activities that could be exploited in drug discovery and development.
Used in Medicinal Chemistry Research:
As a derivative of tetrahydroisoquinoline, 2-(3-chloropropanoyl)-1,2,3,4-tetrahydroisoquinoline may serve as a starting material or a scaffold in medicinal chemistry research. It could be used to explore the structure-activity relationships of potential drug candidates, optimizing their efficacy, selectivity, and pharmacokinetic properties.
Used in Organic Synthesis:
The presence of the 3-chloropropanoyl group may allow for further chemical modifications, making 2-(3-chloropropanoyl)-1,2,3,4-tetrahydroisoquinoline a versatile building block in organic synthesis. It could be employed in the preparation of more complex molecules with diverse applications.

InChI:InChI=1/C12H14ClNO/c13-7-5-12(15)14-8-6-10-3-1-2-4-11(10)9-14/h1-4H,5-9H2

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 625-36-5 2-chloropropionyl chloride 

Relevant academic research and scientific papers

Indole derivatives useful for the treatment of CNS disorders

The present invention relates to dopamine D4 ligands having the general formula I wherein (a) one of Y1 and Y2 is N, which is bound to Y4, and the other of Y1 and Y2 is CO, CS, SO, or SO2 and Y4 is CH2; (b) one of Y1 and Y2 is N, which is bound to Y4, and the other of Y1 and Y2 is CH2 and Y4 is CO, CS, SO or SO2; or (c) one of Y1 and Y2 is N, which is bound to Y4, and the other of Y1 and Y2 is CH2 and Y4 is CH2; Y3is Z—CH2, CH2—Z or CH2CH2, and Z is O or S; provided that when Y1 is N, Y3 may not be Z—CH2; W is a bond or an O, S, CO, CS, SO or SO2 group; n is 0-5, m is 0-5 and m+n is 1-10; provided that when W is O or S, then n≧2 and m≧1; when W is CO, CS, SO or SO2, then n≧1 and m≧1; X is C, CH or N; provided that when X is C, the dotted line indicates a bond, and when X is N or CH, the dotted line is absent; R1-R9 are independently selected from hydrogen, halogen, cyano, nitro, amino, hydroxy, C1-6-alkyl-amino, di-C1-6-alkyl-amino, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6 alkoxy, C1-6-alkylthio, C1-6-alkyl substituted with hydroxy or thiol, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, acyl, thioacyl, aryl, trifluoromethyl, trifluoromethylsulfonyl, and C1-6 alkylsulfonyl; R10 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkyl substituted with hydroxy or thiol, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, aryl, aryl-C1-6-alkyl, acyl, thioacyl, C1-6-alkylsulfonyl, trifluoromethylsulfonyl or arylsulfonyl, or a pharmaceutically acceptable acid addition salt thereof. The compounds of the invention are potent dopamine D4 receptor ligands.